JP2012508215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508215A5 JP2012508215A5 JP2011535129A JP2011535129A JP2012508215A5 JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5 JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- salt according
- optionally
- degrees
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 15
- 239000013078 crystal Substances 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- -1 4-octylphenyl Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 159000000021 acetate salts Chemical group 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- 150000003893 lactate salts Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168862.4 | 2008-11-11 | ||
| EP08168862 | 2008-11-11 | ||
| PCT/EP2009/064889 WO2010055027A2 (en) | 2008-11-11 | 2009-11-10 | Organic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015089480A Division JP2015178503A (ja) | 2008-11-11 | 2015-04-24 | 有機化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508215A JP2012508215A (ja) | 2012-04-05 |
| JP2012508215A5 true JP2012508215A5 (enExample) | 2012-12-20 |
Family
ID=42062355
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535129A Withdrawn JP2012508215A (ja) | 2008-11-11 | 2009-11-10 | 有機化合物 |
| JP2015089480A Withdrawn JP2015178503A (ja) | 2008-11-11 | 2015-04-24 | 有機化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015089480A Withdrawn JP2015178503A (ja) | 2008-11-11 | 2015-04-24 | 有機化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8680146B2 (enExample) |
| EP (1) | EP2358660A2 (enExample) |
| JP (2) | JP2012508215A (enExample) |
| KR (1) | KR20110086142A (enExample) |
| CN (2) | CN105198760A (enExample) |
| AU (1) | AU2009315735B2 (enExample) |
| BR (1) | BRPI0921533A2 (enExample) |
| CA (1) | CA2741974A1 (enExample) |
| CL (1) | CL2011001041A1 (enExample) |
| CO (1) | CO6382154A2 (enExample) |
| EC (1) | ECSP11011121A (enExample) |
| IL (1) | IL212073A0 (enExample) |
| MA (1) | MA32877B1 (enExample) |
| MX (1) | MX2011004924A (enExample) |
| NZ (1) | NZ591999A (enExample) |
| PE (1) | PE20120012A1 (enExample) |
| RU (1) | RU2543621C2 (enExample) |
| TN (1) | TN2011000187A1 (enExample) |
| WO (1) | WO2010055027A2 (enExample) |
| ZA (1) | ZA201102272B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| CN105198760A (zh) * | 2008-11-11 | 2015-12-30 | 诺华股份有限公司 | 芬戈莫德的盐 |
| US8766005B2 (en) | 2009-07-24 | 2014-07-01 | Ratiopharm Gmbh | Process for producing fingolimod salts |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| BR112013010075A2 (pt) | 2010-10-28 | 2017-10-24 | Mapi Pharma Ltd | compostos intermediários e processo para a preparação de fingolimod |
| WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
| EP2505589A1 (en) | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| EP2964210B1 (en) | 2013-03-05 | 2023-10-04 | Biocon Limited | A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof |
| WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| EP3054933A4 (en) | 2013-10-11 | 2017-03-15 | Teikoku Pharma USA, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| CA2996183A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| EP3466934B1 (en) | 2016-05-31 | 2024-03-27 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compounds or salt thereof as ribonucleotide reductase inhibitors for treating cancer |
| RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| AU2018377036B2 (en) | 2017-11-29 | 2022-04-14 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compounds and use thereof |
| US20210261528A1 (en) * | 2018-06-29 | 2021-08-26 | Forma Therapeutics, Inc. | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
| CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| KR20220093330A (ko) | 2019-10-31 | 2022-07-05 | 이도르시아 파마슈티컬스 리미티드 | Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합 |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| US20240262783A1 (en) * | 2021-05-31 | 2024-08-08 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE172711T1 (de) | 1992-10-21 | 1998-11-15 | Yoshitomi Pharmaceutical | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| ECSP951461A (es) | 1995-06-07 | 1998-04-07 | SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B) | |
| ECSP972265A (es) | 1997-09-23 | 1998-11-30 | Dihidrato de d-olanzapina | |
| FR2785607B1 (fr) | 1998-11-09 | 2001-02-09 | Rhodia Chimie Sa | Procede de preparation de tris(ether-amine) |
| WO2000027798A1 (en) * | 1998-11-11 | 2000-05-18 | Novartis Ag | Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols |
| JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| ATE424893T1 (de) * | 2001-06-08 | 2009-03-15 | Novartis Pharma Gmbh | Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung |
| BR0311173A (pt) * | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
| GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| CN101797241B (zh) | 2003-04-08 | 2013-03-27 | 诺瓦提斯公司 | 包含s1p受体激动剂和糖醇的固体药物组合物 |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| JP2009510112A (ja) * | 2005-09-30 | 2009-03-12 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組合せ剤 |
| EP2046315B1 (en) * | 2006-06-02 | 2013-04-10 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of mantle cell lymphoma |
| WO2009100116A1 (en) * | 2008-02-04 | 2009-08-13 | Medical College Of Georgia Research Institute | Oligodendrocyte precursor cell composition and methods of use |
| CN105198760A (zh) * | 2008-11-11 | 2015-12-30 | 诺华股份有限公司 | 芬戈莫德的盐 |
-
2009
- 2009-11-10 CN CN201510547567.5A patent/CN105198760A/zh active Pending
- 2009-11-10 RU RU2011123365/04A patent/RU2543621C2/ru not_active IP Right Cessation
- 2009-11-10 WO PCT/EP2009/064889 patent/WO2010055027A2/en not_active Ceased
- 2009-11-10 EP EP09752168A patent/EP2358660A2/en not_active Withdrawn
- 2009-11-10 MX MX2011004924A patent/MX2011004924A/es active IP Right Grant
- 2009-11-10 US US13/128,832 patent/US8680146B2/en not_active Expired - Fee Related
- 2009-11-10 PE PE2011000987A patent/PE20120012A1/es not_active Application Discontinuation
- 2009-11-10 NZ NZ591999A patent/NZ591999A/xx not_active IP Right Cessation
- 2009-11-10 KR KR1020117013304A patent/KR20110086142A/ko not_active Ceased
- 2009-11-10 BR BRPI0921533A patent/BRPI0921533A2/pt not_active IP Right Cessation
- 2009-11-10 JP JP2011535129A patent/JP2012508215A/ja not_active Withdrawn
- 2009-11-10 CN CN2009801448205A patent/CN102256933A/zh active Pending
- 2009-11-10 AU AU2009315735A patent/AU2009315735B2/en not_active Ceased
- 2009-11-10 CA CA2741974A patent/CA2741974A1/en not_active Abandoned
-
2011
- 2011-03-28 ZA ZA2011/02272A patent/ZA201102272B/en unknown
- 2011-03-31 IL IL212073A patent/IL212073A0/en unknown
- 2011-04-19 TN TN2011000187A patent/TN2011000187A1/fr unknown
- 2011-05-10 CL CL2011001041A patent/CL2011001041A1/es unknown
- 2011-05-12 CO CO11058592A patent/CO6382154A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33910A patent/MA32877B1/fr unknown
- 2011-06-10 EC EC2011011121A patent/ECSP11011121A/es unknown
-
2014
- 2014-02-13 US US14/179,807 patent/US20140235722A1/en not_active Abandoned
-
2015
- 2015-04-24 JP JP2015089480A patent/JP2015178503A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508215A5 (enExample) | ||
| RU2011123365A (ru) | Соли финголимода | |
| RU2011123371A (ru) | Кристаллические формы гидрохлорида финголимода | |
| ES2683355T3 (es) | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades | |
| JP2018035160A5 (enExample) | ||
| HRP20210928T1 (hr) | Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP2010514829A5 (enExample) | ||
| ME02275B (me) | Polimorfni oblik rotigotina | |
| JP2010518061A5 (enExample) | ||
| JP2012523395A5 (enExample) | ||
| JP2009084270A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2011510014A5 (enExample) | ||
| JP2010514831A5 (enExample) | ||
| RU2011145054A (ru) | Кристаллические формы саксаглиптина | |
| JP2010514832A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2010529203A5 (enExample) | ||
| JP2020510661A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 |